Anabella Villalobos
Net worth: 45 600 $ as of 31/08/2026
Net worth: 45 600 $ as of 31/08/2026
Dr. Anabella Villalobos is an Independent Director at Coya Therapeutics, Inc. She is on the Board of Directors at Coya Therapeutics, Inc. Dr. Villalobos was previously employed as a SVP-Biotherapeutics & Medicinal Sciences by Biogen, Inc. and a Vice President by Pfizer Inc. She received her undergraduate degree from the University of Panama and a doctorate degree from the University of Kansas.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/05/2026 | 10,000 ( 0.04% ) | 45 600 $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| COYA THERAPEUTICS, INC. | Director/Board Member | 25/05/2021 |
| Companies | Position | End |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2025 |
| PFIZER INC. | Corporate Officer/Principal | 01/01/2017 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
University of Kansas
University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Panama
University of Panama Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Select your edition
All financial news and data tailored to specific country editions